688639.SHG Anhui Huaheng Biotechnology Co. Ltd. A
- Market cap
- CNY 4.01B
- P/E
- 38.2x
- P/B
- 1.38x
- ROE
- 6.4%
- Dividend yield
- 2.76%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688639.SHG undervalued?
Graham number688639.SHG trades 52.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Anhui Huaheng Biotechnology Co. Ltd. A fundamental analysis
No fundamental analysis for Anhui Huaheng Biotechnology Co. Ltd. A yet.
Anhui Huaheng Biotechnology Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Anhui Huaheng Biotechnology Co. Ltd. A
Anhui Huaheng Biotechnology Co., Ltd. engages in the research and development, production, and sale of bio-based products through bio-manufacturing in China and internationally. The company offers amino acid products, including the alanine series, L-valine, isoleucine, tryptophan, and arginine; vitamin products, such as D-calcium pantothenate, D-panthenol, and inositol; bio-based new material monomers, including 1,3-propanediol and succinic acid; and other products, includin…
Full company profileAnhui Huaheng Biotechnology Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Anhui Huaheng Biotechnology Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 311M | 383M | 421M | 491M | 487M | 954M | 1.42B | 1.94B | 2.18B | 2.86B | 3.17B |
| Gross Profit | 118M | 133M | 167M | 226M | 198M | 308M | 548M | 782M | 540M | 609M | 685M |
| Operating Income | 68.0M | 73.0M | 84.5M | 146M | 132M | 186M | 342M | 511M | 199M | 130M | 240M |
| EBITDA | 85.2M | 101M | 116M | 183M | 178M | 240M | 403M | 618M | 381M | 384M | 208M |
| Net Income | 61.8M | 64.9M | 75.5M | 126M | 121M | 168M | 320M | 449M | 190M | 132M | 175M |
| EPS | 0.77 | 0.39 | 0.45 | 0.74 | 0.71 | 0.81 | 1.41 | 1.96 | 0.82 | 0.53 | 0.70 |
| Balance Sheet | |||||||||||
| Total Assets | 386M | 412M | 541M | 561M | 743M | 1.47B | 2.03B | 3.97B | 4.99B | 5.77B | 6.05B |
| Total Liabilities | 210M | 201M | 231M | 192M | 253M | 291M | 545M | 2.14B | 2.43B | 3.14B | 3.34B |
| Shareholders' Equity | 176M | 211M | 310M | 369M | 490M | 1.18B | 1.48B | 1.83B | 2.56B | 2.65B | 2.74B |
| Cash & Short-term Investments | 53.1M | 24.1M | 62.1M | 54.5M | 62.2M | 463M | 348M | 353M | 423M | 284M | 575M |
| Total Debt | 120M | 85.0M | 100M | 65.1M | 55.1M | 18.5M | 79.2M | 1.22B | 1.32B | 2.10B | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 55.0M | 106M | 89.3M | 181M | 110M | 95.7M | 357M | 304M | 200M | 105M | - |
| Capital Expenditure | 58.8M | 48.0M | 63.4M | 81.7M | 72.6M | 181M | 456M | 1.27B | 924M | 637M | 428M |
| Free Cash Flow | -3.82M | 57.7M | 25.9M | 99.7M | 36.9M | -84.9M | -98.9M | -968M | -724M | -532M | -197M |
| Ratios | |||||||||||
| ROE | 35.1% | 30.8% | 24.3% | 34.3% | 24.7% | 14.2% | 21.6% | 24.6% | 7.4% | 5.0% | 6.4% |
| ROA | 16.0% | 15.7% | 14.0% | 22.5% | 16.3% | 11.4% | 15.8% | 11.3% | 3.8% | 2.3% | 2.9% |
| Net Profit Margin | 19.8% | 17.0% | 17.9% | 25.7% | 24.9% | 17.6% | 22.6% | 23.2% | 8.7% | 4.6% | 5.5% |
| Debt to Equity | 0.68x | 0.40x | 0.32x | 0.18x | 0.11x | 0.02x | 0.05x | 0.67x | 0.51x | 0.79x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Anhui Huaheng Biotechnology Co. Ltd. A dividends
- Dividend yield
- 2.76%
- Forward dividend
- 0.16 CNY
- Payout ratio
- 83.7%
- Ex-dividend date
- May 12, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 111M | 0.44 | 83.7% |
| 2024 | CNY 183M | 0.79 | 96.8% |
| 2023 | CNY 97.6M | 0.43 | 21.7% |
| 2022 | CNY 59.7M | 0.26 | 18.7% |
| 2021 | CNY 36.4M | 0.17 | 21.6% |
| 2020 | CNY 2.86M | 0.02 | 2.4% |
| 2019 | CNY 74.6M | 0.44 | 59.0% |
| 2018 | 4.63M | 0.03 | 6.1% |
| 2017 | 31.7M | 0.19 | 48.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.45:1 on Jul 22, 2024.
Who owns Anhui Huaheng Biotechnology Co. Ltd. A
- Insiders 40.44%
- Institutions 7.59%
- Public & others 51.98%
- Shares outstanding 250M
- Free float 152M
Anhui Huaheng Biotechnology Co. Ltd. A company profile
- Company name
- Anhui Huaheng Biotechnology Co. Ltd. A
- Ticker
- 688639.SHG
- ISIN
- CNE1000052M6
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,252
- Fiscal year end
- December
- Address
- No. 197, Chuangxin Avenue and Chang'an Road, Hefei, China, 231031
- Phone
- 86 551 6568 9046
- Website
- huahengbio.com
About Anhui Huaheng Biotechnology Co. Ltd. A
Anhui Huaheng Biotechnology Co., Ltd. engages in the research and development, production, and sale of bio-based products through bio-manufacturing in China and internationally. The company offers amino acid products, including the alanine series, L-valine, isoleucine, tryptophan, and arginine; vitamin products, such as D-calcium pantothenate, D-panthenol, and inositol; bio-based new material monomers, including 1,3-propanediol and succinic acid; and other products, including malic acid and arbutin. Its products are used in daily chemical products, medicine, health and personal care products, cosmetic products, food additives, feeds, animal nutrition, plant nutrition, and functional food and nutrition. The company was formerly known as Anhui Huaheng Biological Engineering Co., Ltd. and changed its name to Anhui Huaheng Biotechnology Co., Ltd. in November 2013. The company was founded in 2005 and is based in Hefei, China.
Anhui Huaheng Biotechnology Co. Ltd. A management
10- Ms. Henghua GuoChairman of the Board & GM · born 1964
- Mr. Yi FanCFO, Deputy GM & Director · born 1977
- Mr. Xueli ZhangDirector & Core Technical Personnel · born 1981
- Mr. Jian Wen MaoDeputy GM & Director · born 1964
- Mr. Dongzhu ZhangDeputy GM & Director · born 1973
- Mr. Zhong Cheng LiuDeputy General Manager · born 1972
- Xiu Fa ZhuAccounting Supervisor
- Mr. Xian He DengBoard Secretary · born 1989
- Mr. Siqing TangCore technical personnel · born 1982
- Mr. Liu LeiCore technical personnel · born 1987